Stop HB 351 & SB 365: Defining and Scheduling Cannabidiol
0 have signed. Let’s get to 1,000!
Senator Bill O'Neill and Representative Deborah Armstrong have both recently proposed bills which attempt to place Cannabidiol (CBD) under the New Mexico Controlled Substances Act, listing CBD as a Schedule V substance and would only allow pharmaceutical companies with FDA approval to produce CBD products. As of today, there is only one company that has FDA approval, creating a temporary monopoly on CBD that would restrict access to full spectrum extracts in New Mexico. With this bill enacted anyone who seeks the aid of CBD will have limited choices on what they can be prescribed and what they can use for their health. Epidiolex, a prescription CBD medicine currently going through clinical trials, is composed of a Cannabidiol isolate. Recent trials with Epidiolex use on children and young adults who suffer from epilepsy showed 50% reduction in seizures for 39% of patients. While this study is promising, other research has shown better results with epilepsy patients who use Cannabidiol products that are whole plant extracts rather than isolates. The Realm of Caring Foundation conducted a study using the whole plant extract Charlotte’s Web with a group of 107 children with epilepsy, and found that 60% of the patients saw at least a 50% decrease in seizures, while 10% of patients reported being seizure free. It is important that patients and consumers have the ability to choose where their Cannabidiol comes from, so that they have the power to decide what will give them the relief they need. Choice is a powerful determining factor in the Cannabinoid industry.
For a substance to be classified as a Schedule V substance under the Controlled Substances Act, it must meet the following guidelines:
(A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.
Now let's see how Cannabidiol compares to these guidelines
(A) Cannabidiol does have a low potential for abuse, as it is not a psychoactive chemical.
(B) Cannabidiol is known to help with a large variety of ailments, which are recognized by many members of the medical community.
(C) Abuse of CBD, if at all possible, does not lead to dependence to the substance, and some studies even show CBD benefiting those who are dependent on other substances.
Cannabidiol has a wide range of benefits and is used for a variety of reasons, such as anxiety, sleep aid, pain relief, epilepsy, muscle spasms and much more. However, if it becomes required to have a prescription for CBD, some of these ailments may not be considered severe enough to be considered for a Cannabidiol prescription. This bill will hurt those seeking relief more than anyone else.
To stop these bills from going through New Mexico's congress, please sign this petition.
Please contact Senator O'Neill and Representative Armstrong to voice your concern
Senator O’Neill: 505-986-4260
Representative Armstrong: 505-986-4840
Today: Thomas is counting on you
Thomas Martinez needs your help with “Representative Deborah A. Armstrong: Stop HB 351 & SB 365: Defining and Scheduling Cannabidiol”. Join Thomas and 731 supporters today.